


## PHARMACEUTICAL 2021



## Dianthus Therapeutics Inc. DE Rank 106 of 402





## PHARMACEUTICAL 2021



## Dianthus Therapeutics Inc. DE Rank 106 of 402

The relative strengths and weaknesses of Dianthus Therapeutics Inc. DE are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Dianthus Therapeutics Inc. DE compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 73% points. The greatest weakness of Dianthus Therapeutics Inc. DE is the variable Net Income, reducing the Economic Capital Ratio by 23% points.

The company's Economic Capital Ratio, given in the ranking table, is 192%, being 145% points above the market average of 47%.

Input Variable	Value in 1000 USD
Assets, Current	151,527
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	11,430
Liabilities, Non-Current	0
Other Assets	1,780
Other Compr. Net Income	-31
Other Expenses	0
Other Liabilities	6,283
Other Net Income	0
Other Revenues	3,766
Property and Equipment	8,312
Research and Development	50,615
Selling, General and Administrative Expense	28,087

Output Variable	Value in 1000 USD
Assets	161,619
Liabilities	17,713
Expenses	78,702
Revenues	3,766
Stockholders Equity	143,906
Net Income	-74,936
Comprehensive Net Income	-74,952
Economic Capital Ratio	192%

